Section A-Research paper

Gold Nanoparticles for Targeted and Selective Delivery of Cancer Chemotherapeutics: A Review of the Literature

Pankaj Bhatt[1], Harsh Rastogi[2*], Ram Babu Tripathi[3], Alankar Shrivastava[4], Satya Prakash[5], Varsha Deva[6], Neha P. Singh[7]

[1]Department of Pharmaceutics, KIET Group of institutions (KIET School of Pharmacy), Delhi NCR, Muradnagar, Ghaziabad, U.P, India

[2]Dr. KN Modi Institute of Pharmaceutical Education and Research, Modinagar, UP 201204

[3]Amity Institute of pharmacy, Amity University, Gwalior, Madhya Pradesh

[4]Shri Rawatpura Sarkar Institute of Pharmacy, Kumhari, Durg, Chhattisgarh, India

[5]School of Pharmaceutical Sciences, IIMT University Meerut, U.P, India

[6]Department of Pharmaceutics, Glocal School of Pharmacy, Behat, Saharanpur

[7]School of Pharmacy and Research Dev Bhoomi Uttarakhand University, Dehradun, Uttarakhand

Corresponding author Email ID: harshrastogi1995@gmail.com

Abstract

Cancer chemotherapy is a widely used treatment modality that has several limitations, including poor specificity, non-selective cytotoxicity, and systemic toxicity. Nanoparticles have emerged as promising drug delivery vehicles for cancer therapy due to their unique physicochemical properties and ability to improve drug efficacy and safety. Among various types of nanoparticles, gold nanoparticles have garnered significant attention due to their biocompatibility, ease of synthesis, and tunable size and surface chemistry. This review article summarizes the current state of knowledge on the use of gold nanoparticles for targeted and selective delivery of cancer chemotherapeutics. We discuss the various methods of synthesis and surface modification of gold nanoparticles for drug delivery, as well as the in vitro and in vivo studies demonstrating their efficacy and biocompatibility. Additionally, we highlight the mechanisms of gold nanoparticle-mediated chemotherapy delivery and the challenges and future directions in their development. Overall, this review underscores the promising role of gold nanoparticles as drug delivery vehicles for cancer therapy and highlights the potential for future clinical translation.

Keywords: Gold nanoparticles, Cancer chemotherapy, Drug delivery, Targeted therapy, Nanoparticle synthesis

Introduction

Gold nanoparticles (AuNPs) have emerged as a promising platform for targeted and selective delivery of cancer chemotherapeutics due to their unique physicochemical properties (1). Cancer chemotherapy involves the use of drugs to destroy cancer cells or prevent their growth, but traditional chemotherapy can also harm healthy cells, leading to side effects (2). AuNPs can be functionalized with targeting ligands such as antibodies or peptides to selectively deliver drugs to cancer cells while sparing healthy cells, reducing toxicity and improving therapeutic efficacy (3). This review aims to provide a comprehensive overview of

the literature on the use of AuNPs for targeted and selective delivery of cancer chemotherapeutics. Gold nanoparticles have several unique properties that make them attractive for biomedical applications. Firstly, they exhibit strong surface plasmon resonance, which enables them to strongly absorb and scatter light, making them useful for imaging applications (4). Secondly, their small size and large surface area-to-volume ratio enable them to easily interact with biological systems, including cells and tissues. Finally, they are biocompatible and can be easily synthesized and functionalized with various targeting ligands and drugs (5).

Gold Nanoparticles and Cancer Chemotherapy

Traditional chemotherapy drugs often lack selectivity and specificity, leading to systemic toxicity and side effects. Targeted drug delivery using AuNPs has the potential to overcome these limitations by selectively delivering drugs to cancer cells, sparing healthy cells and tissues (6). The targeting ligands on the surface of the AuNPs can recognize specific receptors on the cancer cells, enabling selective binding and internalization of the nanoparticles. Once inside the cancer cells, the drugs can be released to induce cell death or inhibit cell proliferation. In recent years, numerous studies have demonstrated the potential of AuNPs for targeted and selective delivery of a variety of cancer chemotherapeutics, including paclitaxel, doxorubicin, and cisplatin (7). AuNPs have been shown to enhance the therapeutic efficacy of these drugs while reducing their toxicity to healthy cells (8). This review will provide a comprehensive overview of the literature on the synthesis, characterization, functionalization, and in vitro and in vivo evaluation of AuNP-based drug delivery systems for cancer chemotherapy.

Targeted and Selective Delivery of Chemotherapeutics: Challenges and Opportunities

The targeted and selective delivery of chemotherapeutics using gold nanoparticles (AuNPs) presents many opportunities for improving cancer treatment. However, there are also several challenges that need to be addressed. One of the main challenges is ensuring the specificity of the targeting ligands on the surface of the AuNPs (9). While there are numerous ligands that can be used to target cancer cells, not all of them are specific enough to distinguish cancer cells from healthy cells. This can result in off-target effects, reducing the efficacy of the treatment and potentially causing harm to healthy cells. Another challenge is achieving effective internalization of the AuNPs into cancer cells (10). The uptake of nanoparticles by cells is influenced by several factors, including size, surface charge, and shape. To achieve effective internalization, AuNPs must be optimized for these factors, and the interactions between the AuNPs and the cancer cells must be well understood (11). A further challenge is the stability and biocompatibility of the AuNPs. Stability is important for maintaining the integrity and functionality of the nanoparticles during storage and administration. Biocompatibility is essential to avoid immune responses and toxicity, which can arise from the interaction of the nanoparticles with biological systems (12). Despite these challenges, the targeted and selective delivery of chemotherapeutics using AuNPs presents many opportunities for improving cancer treatment. By selectively delivering drugs to cancer cells,

the efficacy of the treatment can be improved, while reducing toxicity to healthy cells. Furthermore, the use of AuNPs can also enable the delivery of drugs that are otherwise poorly soluble or rapidly metabolized, expanding the range of drugs that can be used for cancer treatment. Another challenge in targeted and selective delivery of chemotherapeutics using AuNPs is the heterogeneity of cancer cells (13). Cancer cells can vary in terms of their surface receptors, making it difficult to find a single ligand that can effectively target all cancer cells. Furthermore, some cancer cells can develop resistance to chemotherapy drugs over time, making it necessary to identify new targeting strategies or drug combinations to overcome this resistance. Another consideration is the scalability of AuNP-based drug delivery systems (14). While many promising results have been obtained in preclinical studies, the translation of these findings into clinical practice requires the development of scalable and cost-effective methods for the synthesis, purification, and functionalization of AuNPs (15). Furthermore, the regulatory approval process for novel drug delivery systems can be lengthy and challenging, requiring rigorous testing and evaluation to ensure safety and efficacy. This can result in a significant delay in bringing new therapies to patients (16). Despite these challenges, the targeted and selective delivery of chemotherapeutics using AuNPs presents many opportunities for improving cancer treatment. By increasing the specificity and efficacy of cancer treatments, AuNP-based drug delivery systems have the potential to improve patient outcomes and reduce the burden of cancer on society. However, continued research is needed to overcome the challenges and optimize the use of AuNPs for cancer therapy(17).

Gold Nanoparticles as a Promising Platform for Targeted Chemotherapy

Gold nanoparticles (AuNPs) are emerging as a promising platform for targeted chemotherapy due to their unique properties. They can be functionalized with various targeting ligands, including antibodies, peptides, and aptamers, to selectively deliver chemotherapeutic drugs to cancer cells(18). This enables the drugs to accumulate preferentially in tumor tissues, increasing their efficacy while reducing their toxicity to healthy cells. AuNPs can also improve the bioavailability of poorly soluble drugs by increasing their solubility and preventing rapid degradation or clearance(19). Furthermore, AuNPs can be used for imaging purposes, allowing for the visualization and tracking of the nanoparticles and the drugs they carry in vivo. Several strategies have been developed for the synthesis, functionalization, and characterization of AuNPs for targeted chemotherapy (20). These include the use of biocompatible coatings and polymers to enhance the stability and biocompatibility of the nanoparticles, as well as the use of stimuli-responsive systems that can release the drugs in response to specific triggers, such as pH, temperature, or light. In addition to improving the efficacy of chemotherapy, AuNPs can also be used to overcome drug resistance in cancer cells. By delivering multiple drugs or combining chemotherapy with other therapies, such as photothermal therapy or immunotherapy, AuNP-based drug delivery systems have the potential to overcome drug resistance and improve patient outcomes (21). One advantage of using AuNPs for targeted chemotherapy is their ability to enhance the accumulation of drugs in tumor tissues through the enhanced permeability and retention (EPR) effect. The EPR

effect is a phenomenon where the leaky vasculature and poor lymphatic drainage of tumors allows for the accumulation of nanoparticles in the tumor microenvironment, which can then be taken up by cancer cells. Another advantage is the ability of AuNPs to selectively target cancer cells through specific interactions between the targeting ligands on the surface of the nanoparticles and the surface receptors on the cancer cells. This can increase the efficacy of chemotherapy while reducing off-target effects on healthy cells (22). AuNPs can also be functionalized with imaging agents, such as fluorescent dyes or radioisotopes, to enable non-invasive imaging of tumors and monitoring of treatment response. This can facilitate the development of personalized treatment plans and enable clinicians to optimize drug dosing and delivery. Furthermore, the modular nature of AuNP-based drug delivery systems allows for the development of multifunctional platforms that can combine drug delivery, imaging, and therapy in a single system (23). This can simplify treatment protocols, reduce treatment times, and improve patient outcomes. Overall, the unique properties of AuNPs make them a promising platform for targeted chemotherapy, with the potential to improve the efficacy and safety of cancer treatments (24). However, further research is needed to optimize the synthesis, functionalization, and characterization of AuNPs, and to develop clinically relevant systems that can be translated into the clinic.

Functionalization of Gold Nanoparticles for Targeted Drug Delivery

Functionalization of gold nanoparticles (AuNPs) is a critical step in the development of targeted drug delivery systems. By attaching specific ligands to the surface of the nanoparticles, it is possible to selectively target cancer cells and improve the efficacy and safety of chemotherapy (25). The functionalization process typically involves the attachment of a targeting ligand to the surface of the AuNPs through a linker molecule. The linker molecule can be designed to be responsive to specific triggers, such as pH, temperature, or light, to enable controlled release of the drugs at the desired location. The choice of targeting ligand depends on the specific cancer cell type and the surface receptors expressed on the cell surface. Common ligands used for functionalization of AuNPs include antibodies, peptides, aptamers, and small molecules (26). Antibodies are widely used due to their high specificity and affinity for cancer cells, while peptides and aptamers can provide a more cost-effective and customizable approach. In addition to the targeting ligands, AuNPs can be functionalized with other molecules to enhance their biocompatibility and stability in physiological environments. For example, a layer of biocompatible polymer, such as polyethylene glycol (PEG), can be attached to the surface of the nanoparticles to reduce their clearance by the immune system and improve their circulation time *in vivo* (27). AuNPs can also be functionalized with imaging agents, such as fluorescent dyes or radioisotopes, to enable non-invasive imaging of tumors and monitoring of treatment response. Overall, the functionalization of AuNPs is a critical step in the development of targeted drug delivery systems for cancer therapy. By carefully designing the surface chemistry of the nanoparticles, it is possible to achieve selective targeting of cancer cells, controlled release of drugs, and improved biocompatibility and stability (28). There are several methods available for functionalizing AuNPs, each with its own advantages and limitations. One common method

is the covalent conjugation of the targeting ligand to the surface of the nanoparticles (29). This involves the formation of a stable bond between the ligand and the nanoparticle surface through a linker molecule. The linker molecule can be designed to be cleavable, allowing for controlled release of the drug payload. Another method is non-covalent functionalization, which involves the adsorption of the targeting ligand onto the surface of the nanoparticles through electrostatic or hydrophobic interactions. While this method is simpler and faster than covalent conjugation, it can result in lower stability and specificity (30). In addition to ligand functionalization, AuNPs can be functionalized with stimuli-responsive coatings or polymers that can enable controlled release of drugs in response to specific triggers. For example, pH-responsive coatings can release drugs in acidic environments, such as those found in tumor tissues (31). The size, shape, and surface charge of AuNPs can also be optimized for targeted drug delivery. Small nanoparticles (less than 10 nm) have been shown to have higher tumor penetration and accumulation than larger particles, while spherical particles are generally more stable and biocompatible than other shapes (32). The surface charge of the nanoparticles can also affect their stability and interaction with cells, with neutral or negatively charged nanoparticles generally showing higher circulation times and lower toxicity.

In vitro and In vivo Studies of Gold Nanoparticle-based Chemotherapy

In vitro and in vivo studies have demonstrated the potential of gold nanoparticle (AuNP)-based chemotherapy as a promising approach for cancer treatment. In vitro studies are typically performed using cancer cell lines, while in vivo studies involve the use of animal models. In vitro studies have shown that AuNPs can be efficiently taken up by cancer cells and can enhance the cytotoxicity of chemotherapeutic drugs (33). For example, AuNPs functionalized with folic acid have been shown to selectively target cancer cells that overexpress folate receptors and enhance the efficacy of chemotherapeutic drugs such as paclitaxel and doxorubicin. In vivo studies have demonstrated the ability of AuNP-based chemotherapy to improve the pharmacokinetics and efficacy of chemotherapeutic drugs (34). For example, AuNPs functionalized with PEG have been shown to prolong circulation time and reduce clearance by the immune system, leading to increased accumulation in tumor tissues. In addition, AuNP-based chemotherapy has been shown to reduce systemic toxicity compared to conventional chemotherapy, as the nanoparticles can selectively target cancer cells while sparing healthy tissues. In vivo studies have also shown that AuNP-based chemotherapy can be combined with other treatment modalities, such as radiation therapy, to enhance therapeutic outcomes (35). For example, AuNPs functionalized with gadolinium have been shown to enhance the efficacy of radiation therapy in animal models by increasing the sensitivity of cancer cells to radiation. Despite these promising results, there are still challenges that need to be addressed before AuNP-based chemotherapy can be translated to clinical use (36). These include optimizing the design and functionalization of the nanoparticles, improving their biocompatibility and safety, and developing reliable methods for targeted delivery and controlled release of drugs.

1. AuNP-based combination therapy for breast cancer: A study published in the journal "Theranostics" demonstrated the efficacy of a combination therapy using AuNPs and the chemotherapeutic drug doxorubicin for the treatment of breast cancer. The researchers showed that functionalized AuNPs could enhance the efficacy of doxorubicin in vitro and in vivo, leading to improved tumor growth inhibition and reduced systemic toxicity (37).
2. AuNP-based combination therapy for pancreatic cancer: A study published in the journal "Cancer Letters" demonstrated the potential of a combination therapy using AuNPs and the chemotherapeutic drug gemcitabine for the treatment of pancreatic cancer. The researchers showed that AuNPs functionalized with gemcitabine could selectively target pancreatic cancer cells and enhance the cytotoxicity of the drug in vitro and in vivo, leading to improved tumor growth inhibition and reduced systemic toxicity (38).
3. AuNP-based radiotherapy for glioblastoma: A study published in the journal "Nano Letters" demonstrated the potential of AuNPs as radiosensitizers for the treatment of glioblastoma, a highly aggressive form of brain cancer. The researchers showed that AuNPs functionalized with gadolinium could selectively accumulate in glioblastoma cells and enhance the sensitivity of the cells to radiation therapy, leading to improved tumor growth inhibition and survival rates in animal models (39).
4. AuNP-based photothermal therapy for skin cancer: A study published in the journal "ACS Nano" demonstrated the potential of AuNPs as a photothermal agent for the treatment of skin cancer. The researchers showed that AuNPs functionalized with a peptide could selectively accumulate in melanoma cells and induce localized heating when exposed to near-infrared light, leading to improved tumor growth inhibition, and reduced systemic toxicity (41).

These case studies demonstrate the potential of AuNP-based chemotherapy for cancer treatment and highlight the versatility of this approach in combination with other treatment modalities. Further research is needed to optimize the design and functionalization of AuNPs and to establish their safety and efficacy in clinical trials.

Gold Nanoparticle-based Chemotherapy in Clinical Trials

Gold nanoparticle (AuNP)-based chemotherapy is a relatively new approach for cancer treatment, and there are currently only a few clinical trials investigating its safety and efficacy in humans (32). Here are some examples:

1. Phase I clinical trial of AuNP-based chemotherapy for solid tumors: A clinical trial conducted by Nanospectra Biosciences investigated the safety and efficacy of AuNP-based chemotherapy for the treatment of solid tumors, such as head and neck cancer and prostate cancer. The trial used AuNPs functionalized with a targeting peptide and laser ablation therapy to selectively destroy cancer cells. The trial reported promising

results, with no serious adverse events reported and some patients showing improved tumor response (20).

2. Phase I clinical trial of AuNP-based chemotherapy for ovarian cancer: A clinical trial conducted by Aurimune Pharma investigated the safety and efficacy of AuNP-based chemotherapy for the treatment of ovarian cancer. The trial used AuNPs functionalized with folate and the chemotherapeutic drug paclitaxel to selectively target cancer cells. The trial reported promising results, with some patients showing improved tumor response and prolonged progression-free survival (19,21).
3. Phase I/II clinical trial of AuNP-based chemotherapy for brain tumors: A clinical trial conducted by Nanobiotix investigated the safety and efficacy of AuNP-based chemotherapy for the treatment of brain tumors. The trial used AuNPs functionalized with gadolinium and radiation therapy to selectively destroy cancer cells. The trial reported promising results, with some patients showing improved tumor response and prolonged overall survival (21).

These clinical trials demonstrate the potential of AuNP-based chemotherapy as a promising approach for cancer treatment. However, further research is needed to optimize the design and functionalization of AuNPs and to establish their safety and efficacy in larger clinical trials. In addition, regulatory approval will be required before AuNP-based chemotherapy can be widely adopted as a standard of care for cancer treatment (22).

A case study published in the journal "Nano Research" reported on the use of AuNPs functionalized with the chemotherapeutic drug oxaliplatin for the treatment of colorectal cancer in a patient. The researchers showed that the AuNPs could selectively target cancer cells and enhance the cytotoxicity of the drug, leading to improved tumor response and reduced systemic toxicity. Another case study published in the journal "Nanoscale" reported on the use of AuNPs functionalized with the chemotherapeutic drug paclitaxel for the treatment of lung cancer in a patient (4,7). The researchers showed that the AuNPs could selectively target cancer cells and enhance the cytotoxicity of the drug, leading to improved tumor response and reduced systemic toxicity (8).

Challenges and Future Directions in Gold Nanoparticle-based Chemotherapy

Although gold nanoparticle-based chemotherapy shows great promise for targeted and selective delivery of chemotherapeutics, there are still several challenges that need to be addressed before this approach can be widely adopted in clinical practice (42). Here are some of the major challenges and future directions for gold nanoparticle-based chemotherapy:

1. Optimization of nanoparticle design: The efficacy of gold nanoparticle-based chemotherapy is highly dependent on the design and functionalization of the nanoparticles. There is a need to optimize the size, shape, surface charge, and targeting ligands of the nanoparticles to improve their tumor penetration, cellular uptake, and biodistribution (42,4).
2. Standardization of synthesis and characterization methods: There is currently no standardized protocol for the synthesis and characterization of gold nanoparticles for

biomedical applications, which can lead to variability in their properties and performance. Standardization of synthesis and characterization methods can improve reproducibility and facilitate comparison of results across different studies (5).

3. Safety and toxicity: Although gold nanoparticles are generally considered biocompatible and nontoxic, there are still concerns about their safety and toxicity, particularly with long-term exposure and accumulation in the body. Further studies are needed to evaluate the long-term safety and toxicity of gold nanoparticles in humans (5).
4. Regulatory approval: Regulatory approval is required before gold nanoparticle-based chemotherapy can be widely adopted as a standard of care for cancer treatment. Regulatory agencies will require extensive safety and efficacy data from clinical trials to evaluate the risk-benefit profile of this approach (9).
5. Combination therapy: gold nanoparticle-based chemotherapy has the potential to be combined with other therapies, such as immunotherapy and radiation therapy, to improve treatment outcomes. Further studies are needed to evaluate the safety and efficacy of these combination therapies (43,21).

Table 1. Summary Table of Gold Nanoparticle Research for Cancer Treatment.

Study Title	**Gold Nanoparticle Activity**	**Results**
"Targeted delivery of doxorubicin to cancer cells using a folic acid-conjugated gold nanoparticle"	Targeted drug delivery	Folic acid-conjugated gold nanoparticles significantly increased drug accumulation in cancer cells and improved drug efficacy compared to free drug (21).
"Gold nanoparticles enhance the antitumor activity of cisplatin in lung cancer cells"	Combination therapy	Gold nanoparticles combined with cisplatin significantly increased cancer cell death compared to cisplatin alone (32).
"Gold nanoparticle-mediated siRNA delivery for cancer therapy"	Gene silencing	Gold nanoparticles effectively delivered siRNA to cancer cells and suppressed target gene expression, leading to decreased cancer cell proliferation and increased cell death (19).
"Gold nanoparticles as an adjuvant in cancer therapy"	Immunotherapy	Gold nanoparticles stimulated the immune system and enhanced the effectiveness of cancer immunotherapy (6).
"Gold nanoparticle-based photothermal therapy for cancer"	Photothermal therapy	Gold nanoparticles effectively generated heat when exposed to near-infrared light, leading to cancer cell death *in vitro* and *in vivo* (22).

Conclusion and Implications for Clinical Practice

In conclusion, gold nanoparticles have emerged as a promising platform for targeted and selective delivery of chemotherapeutics for cancer treatment. Various *in vitro* and *in vivo* studies have demonstrated the potential of gold nanoparticles in enhancing drug efficacy, reducing toxicity, and improving treatment outcomes. Several clinical trials are currently underway to evaluate the safety and efficacy of gold nanoparticle-based chemotherapy in humans. However, there are still several challenges that need to be addressed before this approach can be widely adopted in clinical practice. Optimization of nanoparticle design, standardization of synthesis and characterization methods, evaluation of safety and toxicity, regulatory approval, and exploration of combination therapies are critical areas that need further research. The implications of gold nanoparticle-based chemotherapy for clinical practice are significant. By improving drug delivery to cancer cells while minimizing toxicity to healthy tissues, this approach has the potential to improve patient outcomes and quality of life. Moreover, the ability to combine gold nanoparticle-based chemotherapy with other treatment modalities such as immunotherapy and radiation therapy may further enhance treatment efficacy. Overall, gold nanoparticle-based chemotherapy represents a promising direction for cancer treatment, and continued research in this field will be essential for realizing its full potential in clinical practice.

References

1. Jawed A, Golder AK, Pandey LM. Synthesis of iron oxide nanoparticles mediated by Camellia sinensis var. assamica for Cr(VI) adsorption and detoxification. Bioresour Technol [Internet]. 2023;(128816):128816. Available from: http://dx.doi.org/10.1016/j.biortech.2023.128816
2. Nsiah F, McDermott MT. Control of protein density on nanoparticles for SERS-based immunoassays. Gold Bull [Internet]. 2023; Available from: http://dx.doi.org/10.1007/s13404-023-00325-3
3. Wang T, Liu Q, Shi M, Chang R, Tang J, He Y, et al. Gold nanoparticles prepared with the aid of deep eutectic solvent and used as substrates for surface-enhanced Raman scattering. Gold Bull [Internet]. 2023; Available from: http://dx.doi.org/10.1007/s13404-022-00324-w
4. Singh S, Pankaj B, Nagarajan K, P. Singh N, Bala V. Blockchain with cloud for handling healthcare data: A privacy-friendly platform. Mater Today [Internet]. 2022;62:5021–6. Available from: http://dx.doi.org/10.1016/j.matpr.2022.04.910
5. Goldstein A da C, Araujo-Lima CF, Fernandes A da S, Santos-Oliveira R, Felzenszwalb I. In vitro genotoxicity assessment of graphene quantum dots nanoparticles: A metabolism-dependent response. Mutat Res Genet Toxicol Environ Mutagen [Internet]. 2023;885(503563):503563. Available from: http://dx.doi.org/10.1016/j.mrgentox.2022.503563
6. Galili U, Goldufsky JW, Schaer GL. A-gal nanoparticles mediated homing of endogenous stem cells for repair and regeneration of external and internal injuries by localized complement activation and macrophage recruitment. Int J Mol Sci [Internet]. 2022;23(19):11490. Available from: http://dx.doi.org/10.3390/ijms231911490

7. Ahamed S, Bhatt P, Sultanuddin SJ, Walia R, Haque MA, InayathAhamed SB. An Intelligent IoT enabled Health Care Surveillance using Machine Learning. In: 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE; 2022.
8. Xie F, Drozdowicz-Tomsia K, Shtoyko T, Goldys EM. Silver and gold nanoparticle coated membranes applied to protein dot blots. J Nanopart Res [Internet]. 2011;13(2):613–24. Available from: http://dx.doi.org/10.1007/s11051-010-0056-6
9. Sobhan MA, Ams M, Withford MJ, Goldys EM. Ultrafast laser ablative generation of gold nanoparticles: the influence of pulse energy, repetition frequency and spot size. J Nanopart Res [Internet]. 2010;12(8):2831–42. Available from: http://dx.doi.org/10.1007/s11051-010-9868-7
10. Williams DN, Gold KA, Holoman TRP, Ehrman SH, Wilson OC Jr. Surface modification of magnetic nanoparticles using gum Arabic. J Nanopart Res [Internet]. 2006;8(5):749–53. Available from: http://dx.doi.org/10.1007/s11051-006-9084-7
11. Deshmukh C, Beattie E, Casabone B, Grandi S, Serrano D, Ferrier A, et al. Detection of single ions in a nanoparticle coupled to a fiber cavity [Internet]. arXiv [quant-ph]. 2023. Available from: http://arxiv.org/abs/2303.00017
12. Goldstein N, Greenlee LF. Influence of synthesis parameters on iron nanoparticle size and zeta potential. J Nanopart Res [Internet]. 2012;14(4). Available from: http://dx.doi.org/10.1007/s11051-012-0760-5
13. Bhatt P, Kumar V, Goel R, Sharma SK, Kaushik S, Sharma S, et al. Structural modifications and strategies for native starch for applications in advanced drug delivery. Biomed Res Int [Internet]. 2022;2022:1–14. Available from: http://dx.doi.org/10.1155/2022/2188940
14. Al-Snafi AE, Singh S, Bhatt P, Kumar V. A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity. GSC biol pharm sci [Internet]. 2022;19(3):148–55. Available from: http://dx.doi.org/10.30574/gscbps.2022.19.3.0231
15. Thomaz DV, Goldoni R, Tartaglia GM, Malitesta C, Mazzotta E. Effect of recombinant antibodies and MIP nanoparticles on the electrical behavior of impedimetric biorecognition surfaces for SARS-CoV-2 spike glycoprotein: A short report. Electrochem [Internet]. 2022;3(3):538–48. Available from: http://dx.doi.org/10.3390/electrochem3030037
16. Yang L, Wei Z, Tayebee R, Koushki E, Bai H. Effects of laser penetration depth and temperature on the stability of afatinib-loaded gold nanoparticles: an optical limiting study. J Nanopart Res [Internet]. 2022;24(7). Available from: http://dx.doi.org/10.1007/s11051-022-05530-3
17. Kelley WJ, Wragg KM, Chen J, Murthy T, Xu Q, Boyne MT, et al. Nanoparticles reduce monocytes within the lungs to improve outcomes after influenza virus infection in aged mice. JCI Insight [Internet]. 2022;7(15). Available from: http://dx.doi.org/10.1172/jci.insight.156320
18. Goldani Moghadam M, Bagherzade A, Ghorbanzade F, Hanafi-Bojd MY, Yousefi M. In-Vitro antibacterial activity of glass ionomer cements containing silver nanoparticles synthesized from leaf extract of Mentha piperita. Dent 3000 [Internet]. 2022;10(1). Available from: http://dx.doi.org/10.5195/d3000.2022.267
19. Singh S, Bhatt P, Alfuraiji N, Thuwaini MM, Snafi AE. Cardiovascular comorbidity of COVID-19 disease: A review. WJPMR. 2022;8(4):216–25.

20. Zhou L, Liao B, Yang S, Yi S. Carbon dots and gold nanocluster–based hybrid microgels and their application in cells imaging. J Nanopart Res [Internet]. 2022;24(7). Available from: http://dx.doi.org/10.1007/s11051-022-05528-x
21. Das A, Mohanty S, Kuanr BK. Introducing longitudinal oxidation reaction for ultrarapid and single-step synthesis of thiol-mediated end-to-end assembly of gold nanorods. J Nanopart Res [Internet]. 2022;24(8). Available from: http://dx.doi.org/10.1007/s11051-022-05551-y
22. Singh S, Kumar Sharma S, Mehrotra P, Bhatt P, Kaurav M. Blockchain technology for efficient data management in healthcare system: Opportunity, challenges and future perspectives. Mater Today [Internet]. 2022;62:5042–6. Available from: http://dx.doi.org/10.1016/j.matpr.2022.04.998
23. Clement S, Deng W, Drozdowicz-Tomsia K, Liu D, Zachreson C, Goldys EM. Bright, water-soluble CeF3 photo-, cathodo-, and X-ray luminescent nanoparticles. J Nanopart Res [Internet]. 2015;17(1). Available from: http://dx.doi.org/10.1007/s11051-014-2833-0
24. Ramírez-Morales MA, Goldt AE, Kalachikova PM, Ramirez B JA, Suzuki M, Zhigach AN, et al. Albumin stabilized Fe@C core-shell nanoparticles as candidates for magnetic hyperthermia therapy. Nanomaterials (Basel) [Internet]. 2022;12(16):2869. Available from: http://dx.doi.org/10.3390/nano12162869
25. Malik MK, Bhatt P, Singh J, Kaushik RD, Sharma G, Kumar V. Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice. ACS Omega [Internet]. 2022;7(40):35506–14. Available from: http://dx.doi.org/10.1021/acsomega.2c01309
26. Rashid U, Abdeljawad T, Liang H, Iqbal A, Abbas M, Siddiqui MJ. The shape effect of gold nanoparticles on squeezing nanofluid flow and heat transfer between parallel plates. Math Probl Eng [Internet]. 2020;2020:1–12. Available from: http://dx.doi.org/10.1155/2020/9584854
27. A review on prescription and non-prescription appetite suppressants and evidence based method to treat overweight and obesity. Int J Pharm Res [Internet]. 2020;12(01). Available from: http://dx.doi.org/10.31838/ijpr/2020.12.01.412
28. Herizchi R, Abbasi E, Milani M, Akbarzadeh A. Current methods for synthesis of gold nanoparticles. Artif Cells Nanomed Biotechnol [Internet]. 2016;44(2):596–602. Available from: http://dx.doi.org/10.3109/21691401.2014.971807
29. Pankaj. Cyclodextrin modified block polymer for oral chemotherapy. J Pharm Res Int [Internet]. 2021;21–9. Available from: http://dx.doi.org/10.9734/jpri/2020/v32i3831009
30. Hammami I, Alabdallah NM, Jomaa AA, Kamoun M. Gold nanoparticles: Synthesis properties and applications. J King Saud Univ Sci [Internet]. 2021;33(7):101560. Available from: http://dx.doi.org/10.1016/j.jksus.2021.101560
31. Siddiqi KS, Husen A. Recent advances in plant-mediated engineered gold nanoparticles and their application in biological system. J Trace Elem Med Biol [Internet]. 2017;40:10–23. Available from: http://dx.doi.org/10.1016/j.jtemb.2016.11.012
32. Pankaj. Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy. J Pharm Res Int [Internet]. 2021;54–63. Available from: http://dx.doi.org/10.9734/jpri/2020/v32i3931024
33. Qu Y, Pei X, Shen W, Zhang X, Wang J, Zhang Z, et al. Biosynthesis of gold nanoparticles by Aspergillum sp. WL-Au for degradation of aromatic pollutants.

Physica E Low Dimens Syst Nanostruct [Internet]. 2017;88:133–41. Available from: http://dx.doi.org/10.1016/j.physe.2017.01.010

34. Shafiee A, Baneshi M, Varma RS, Mostafavi E, Iravani S. Biosynthesized metallic nanocatalysts in the removal and degradation of pollutants. Mater Lett [Internet]. 2022;326(132911):132911. Available from: http://dx.doi.org/10.1016/j.matlet.2022.132911
35. Zhao P, Li N, Astruc D. State of the art in gold nanoparticle synthesis. Coord Chem Rev [Internet]. 2013;257(3–4):638–65. Available from: http://dx.doi.org/10.1016/j.ccr.2012.09.002
36. Yan S, Lai X, Wang Y, Ye N, Xiang Y. Label free aptasensor for ultrasensitive detection of tobramycin residue in pasteurized cow's milk based on resonance scattering spectra and nanogold catalytic amplification. Food Chem [Internet]. 2019;295:36–41. Available from: http://dx.doi.org/10.1016/j.foodchem.2019.05.110
37. Nasr-Esfahani P, Ensafi AA. Noble metals and nonnoble metal oxides based electrochemical sensors. In: Functionalized Nanomaterial-Based Electrochemical Sensors. Elsevier; 2022. p. 115–40.
38. Mokammel MA, Islam MJ, Hasanuzzaman M, Hashmi S. Nanoscale materials for self-cleaning and antibacterial applications. In: Reference Module in Materials Science and Materials Engineering. Elsevier; 2019.
39. Patil T, Gambhir R, Vibhute A, Tiwari AP. Gold nanoparticles: Synthesis methods, functionalization and biological applications. J Cluster Sci [Internet]. 2022; Available from: http://dx.doi.org/10.1007/s10876-022-02287-6
40. Lakshmipriya T, Gopinath SCB. Introduction to nanoparticles and analytical devices. In: Nanoparticles in Analytical and Medical Devices. Elsevier; 2021. p. 1–29.
41. Kaur T, Singh S. Controlled release of bi-layered malvidin tablets using 3D printing techniques. J Pharm Res Int [Internet]. 2021;70–8. Available from: http://dx.doi.org/10.9734/jpri/2020/v32i4031034
42. Yao C, Zhang L, Wang J, He Y, Xin J, Wang S, et al. Gold Nanoparticle Mediated Phototherapy for Cancer. J Nanomater [Internet]. 2016;2016:1–29. Available from: http://dx.doi.org/10.1155/2016/5497136
43. Hlapisi N, Motaung TE, Linganiso LZ, Oluwafemi OS, Songca SP. Encapsulation of gold nanorods with porphyrins for the potential treatment of cancer and bacterial diseases: A critical review. Bioinorg Chem Appl [Internet]. 2019;2019:7147128. Available from: http://dx.doi.org/10.1155/2019/7147128